Analysts Set Bionano Genomics, Inc. (NASDAQ:BNGO) Target Price at $7.50

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) have earned a consensus rating of “Hold” from the four research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.50.

A number of analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 price objective (up previously from $10.00) on shares of Bionano Genomics in a report on Monday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bionano Genomics in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th.

Bionano Genomics Stock Down 1.6%

BNGO stock opened at $1.79 on Tuesday. The company has a market cap of $7.41 million, a P/E ratio of -0.08 and a beta of 2.19. Bionano Genomics has a 52 week low of $1.50 and a 52 week high of $22.80. The company’s 50-day moving average price is $2.58 and its 200 day moving average price is $3.23. The company has a current ratio of 1.76, a quick ratio of 1.41 and a debt-to-equity ratio of 0.08.

Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.70. The firm had revenue of $6.73 million for the quarter, compared to the consensus estimate of $6.90 million. Bionano Genomics had a negative net margin of 271.02% and a negative return on equity of 129.41%. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Institutional Trading of Bionano Genomics

A hedge fund recently bought a new stake in Bionano Genomics stock. Everstar Asset Management LLC acquired a new stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 44,984 shares of the company’s stock, valued at approximately $126,000. Everstar Asset Management LLC owned 1.45% of Bionano Genomics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.